Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-989-5
CAS number: 732-26-3
Absorption is rapid and extensive. Clearance from plasma is rapid. Most of this compound after disappearing from the blood moves into adipose tissue. The blood elimination half-lives were 18.2 minutes for the α-phase and 11.8 hours for the slower β-phase. A metabolite (but no parent) was detected in the faeces. The faecal metabolite had a molecular weight of 261 and was considered to be 2,4,6-tri-tbutylphenoxy radical. The phenoxy radical was also detected in the bile of rats.
In the study performed by Takahashi O & Hiraga K (1983) single oral
doses (up to 260 mg/kg bw) were well absorbed in the Sprague Dawley rat.
Peak blood levels of the test material were reached in 15 to 60 minutes.
The blood elimination half-lives were 18.2 minutes for the α-phase and
11.8 hours for the slower β-phase. Maximum tissue concentrations were
reached after 2 to 3 hours in the liver, 2 to 6 hours in the kidneys,
1.5 to 2.5 hours in the spleen and >24 hours in epididymal adipose
Most of this compound after disappearing from the blood moved into
adipose tissue. It was not metabolised to less lipophilic compounds.
Therefore excretion of the material from plasma is rapid (t ½ alpha),
but the material that gets into fat is more slowly released from fat
back into plasma (t ½ beta). The
rather short β-phase halfe-life though is not indicative of
bioaccumulation of the substance in rats.
The test material and its metabolites were not excreted in the urine. A
metabolite (but no parent) was detected in the faeces. The faecal
metabolite had a molecular weight of 261 and was considered to be
2,4,6-tri-tbutylphenoxy radical. The phenoxy radical was also detected
in the bile of rats.
On the basis of the absence of parent in the faeces and the extremely
rapid clearance from the blood, absorption across the GIT is considered
to be 100%.
In the absence of an quantitative information, inhalation absorption is
set at 100 % for risk assessment purposes.
Oral data would indicate rapid diffusion of the substance across the gut
hence its physical chemical properties (MW 262, water solubility 0.512
mg/L at 25 °C, Kow 6) do not hinder absorption in this regard. Hence
adoption of the conservative default dermal absorption value of 25 %,
based on EFSA guidance on dermal absorption (2012), is considered
appropriate for risk assessment purposes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Deze website maakt gebruik van cookies om het surfen zo aangenaam mogelijk te maken.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again